Kvalitet i läkemedelsanvändningen vid astma : En jämförande analys (tvärsnittsstudie) mellan luftvägsregistret och läkemedelsregistret, 2016–2020.

Sammanfattning: Quality of drug use in asthma Background: The National Airway Register is a quality register, which provides opportunities for quality follow-up and improvement. It contains data on individuals with asthma disease, their drug treatment and outcomes obtained in health care.  Aim: To examine how representative data on drug treatment contained in the National Airway Register are for adult patients with asthma in Region Stockholm and Sweden, respectively. Methods: A cross-sectional study based on data from the National Airway Register and the Prescribed Drug Register, where the study population consisted of asthma patients aged 18-44. Open data from the Prescribed Drug Register was limited to 15–44-year-old patients. Data were collected for the period 2016–2020 regarding drugs within ATC code R03 and dupilumab with ATC code D11AH05.  Results: A difference in the use of asthma drugs between the National Airway Register and Prescribed Drug Register with the same trend for all studied years was seen. In the National Airway Register, the proportion of individuals who used bronchodilators without having obtained any ICS was lower and a higher proportion (74-82% vs 65-70%) had obtained ICS. Drugs administered in clinics cannot be studied in the Prescribed Drug Register. Conclusions: Drug treatment in the National Airway Register generally seems to comply better with international guidelines than in the Prescribed Drug Register, which may be an indication that the quality of asthma treatment is higher for patients registered in the National Airway Register. This causes problems in generalizability since obtained data only correspond to individuals who are selected.